Login / Signup

BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.

Francesca De SantisSandra L Romero-CordobaLorenzo CastagnoliTatiana VolpariSimona FaraciGiovanni FucàElda TagliabueFilippo De BraudSerenella M PupaMassimo Di Nicola
Published in: Cellular oncology (Dordrecht) (2022)
Our results may be instrumental for the prospective design of combination treatment strategies that selectively target novel TNBC-associated biomarker(s) whose activity is implicated in the regulation of cancer stemness (such as BCL6) and molecules in developmentally conserved signaling pathways (such as Notch) to achieve long-lasting tumor control and improve patient outcomes.
Keyphrases